Pulmonary arterial hypertension (PAH) impacts multiple aspects of patients’ and caregivers’ lifes, a new survey from China shows. The study,…
Articles by José Lopes, PhD
More than 2,000 letters urge Canadian health authorities to make all pulmonary arterial hypertension (PAH) therapies available through public funding…
Pfizer’s Phase 4 clinical trial (NCT00323297) in pulmonary arterial hypertension (PAH) shows no clinical benefits of adding…
Bayer’s Adempas (riociguat) can improve the lung and heart functioning of pulmonary hypertension patients who fail to respond to phosphodiesterase-5…
Uptravi (selexipag) slows the progression of connective tissue disease associated with pulmonary arterial hypertension, regardless of the type of connective tissue…
Early renal denervation (RDN) treatment improved pulmonary arterial hypertension (PAH) in a rat model, a new study from China showed.
Pulmonary arterial hypertension (PAH) patients have given high marks to a new implanted,  programmable intravenous (IV) system that delivered Remodulin (treprostinil)…
Chronic thromboembolic pulmonary hypertension (CTEPH) may be mitigated by pulmonary thromboendarterectomy, which prevents the need for lung transplant, a new…
A variation in the gene sequence of superoxide dismutase 2 (SOD2) is associated with a susceptibility to pulmonary arterial hypertension (PAH),…
People newly diagnosed with pulmonary arterial hypertension (PAH) in Portugal have survival rates similar to those in other developed countries…